We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

POLX Polarean Imaging Plc

-0.10 (-7.41%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Polarean Imaging Plc LSE:POLX London Ordinary Share GB00BF3DT583 ORD GBP0.00037
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -7.41% 1.25 1.20 1.30 1.35 1.225 1.35 6,289,561 15:41:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 1.03M -13.91M -0.0644 -0.19 2.7M

Polarean Imaging PLC Exercise of Warrants, Issue of Equity and TVR

14/03/2024 7:00am

RNS Regulatory News

RNS Number : 7523G
Polarean Imaging PLC
14 March 2024

Polarean Imaging Plc

("Polarean" or the "Company") 


Exercise of Warrants, PDMR Dealing, Issue of Equity and Total Voting Rights


Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging ("MRI") of the lungs, announces that it has received notification from Dr. Bastiaan Driehuys, Chief Technology Officer and Director, to exercise 148,456 warrants over ordinary shares in the Company (the "Warrants"). These warrants representing 148,456 ordinary shares of £0.00037 each in the capital of the Company ("Ordinary Shares") have an exercise price of US$0.00037 per Ordinary Share. Dr. Driehuys has indicated that he does not plan to sell any of these shares at the present time.


After the exercise of the Warrants, Dr. Driehuys holds a total of 12,415,959 Ordinary Shares and options for 1,686,000 Ordinary Shares.


The 148,456 new Ordinary Shares have been issued and admitted to trading on AIM pursuant to the Block Listing announced by the Company on 23 July 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.


Notifications have been made in accordance with the requirements of the UK Market Abuse Regulation in respect of the PDMR and further details can be found by following this link:


Total voting rights


Following the issue and allotment of the Ordinary Shares, the Company's issued share capital comprises 216,264,249 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 216,264,249.


The figure of 216,264,249 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.



Polarean Imaging plc /

Christopher von Jako, Ph.D, Chief Executive Officer

Via Walbrook PR

Charles Osborne, Chief Financial Officer



Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)

Nick Adams / Nick Harland (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or

Anna Dunphy / Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082




About Polarean (

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. The Company also commercialises systems (such as the HPX hyperpolarisation system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

1 Year Polarean Imaging Chart

1 Year Polarean Imaging Chart

1 Month Polarean Imaging Chart

1 Month Polarean Imaging Chart

Your Recent History

Delayed Upgrade Clock